In her new role, Ms Wolf will be responsible for the creation and implementation of reimbursement strategies and policies. As Axial’s liaison to the laboratory community, she will continue her active role in matters relating to reimbursement and regulatory initiatives that impact molecular diagnostics.
In her most recent role as vice president of reimbursement and regulatory affairs with RedPath Integrated Pathology, Ms Wolf was responsible for creating and managing all billing polices and activities, patient advocacy programs, and public and private payer coverage and contracting.
Prior to joining RedPath, Ms Wolf was the director of reimbursement and payer relations for Genomic Health, where she helped to develop reimbursement strategies and programs that led to positive coverage policies with major third party payers, as well as a favorable local coverage determination from Genomic Health’s Part B Medicare Carrier.
John Climaco, president and CEO of Axial Biotech, said: “One of the key components of Axial’s future success will be achieving appropriate levels of insurance coverage for our products and Ms Wolf’s vast experience in this area is second to none. In addition, she brings to our company an unparalleled level of understanding of the complex and rapidly evolving regulatory landscape around molecular diagnostics.”